| Document |
Document Title |
|
JPH0146499B2 |
|
|
JPH0146504B2 |
The invention provides new derivatives of vitamin D, 24,24-difluoro-1 alpha ,25-dihydroxycholecalciferol and 24,24-difluoro-1 alpha ,25-dihydroxy-5,6-trans-cholecalciferol and processes for preparing the same. The compounds are character...
|
|
JPH0145460B2 |
Polyunsaturated ketones of formula (I) having a double bond in position 2' or 3' of the side chain and possessing either an isolated double bond in position 1 or 2, or two conjugated double bonds in positions 1 and 3 of the ring, as indi...
|
|
JPH0144696B2 |
|
|
JPH0144698B2 |
|
|
JPH0144699B2 |
|
|
JPH0144695B2 |
The vitamin D3 derivative 1 alpha ,25,26-trihydroxycholecalciferol which is useful for regulating the calcium metabolism or calcium transport in the body, cholestene intermediates and a process for their preparation are described.
|
|
JPH0144697B2 |
|
|
JPH0144172B2 |
An E-type prostaglandin in a solvent comprising a mixture of triacetin and ethanol, which has good stability and is rapidly miscible with water.
|
|
JPH01502750A |
PCT No. PCT/DE88/00151 Sec. 371 Date Nov. 23, 1988 Sec. 102(e) Date Nov. 23, 1988 PCT Filed Mar. 11, 1988 PCT Pub. No. WO88/07037 PCT Pub. Date Sep. 22, 1988.The invention relates to 6-oxo-prostaglandin E1 derivatives of formula I, (I) i...
|
|
JPH0142944B2 |
The invention provides a new derivative of vitamin D3, 24,24-difluoro-25-hydroxycholecalciferol. The compound is characterized by vitamin D-like activity in its ability to increase intestinal calcium transport, increase serum calcium and...
|
|
JPH0142945B2 |
|
|
JPH0142957B2 |
|
|
JPH0142264B2 |
|
|
JPH0142266B2 |
|
|
JPH0142265B2 |
|
|
JPH0141625B2 |
The present invention is directed to new 16-methoxy-16-methyl prostaglandin E1 derivatives of the following general formula wherein R stands for a (C1-4) alkyl group or a non-toxic pharmaceutically acceptable cation, to a process for pre...
|
|
JPH0141624B2 |
|
|
JPH0141623B2 |
Described is a process for preparing beta -damascone starting with 2,6,6-trimethyl cyclohex-2-enone according to the reaction sequence: wherein Z is hydrogen MgX min , Li, Na or K; Y is MgX min , Li, Na or K; X min is Cl, Br or I; R is C...
|
|
JPH0141139B2 |
|
|
JPH0141147B2 |
|
|
JPH0141144B2 |
|
|
JPH0141146B2 |
|
|
JPH0141145B2 |
|
|
JPH0141140B2 |
|
|
JPH0141142B2 |
|
|
JPH0141143B2 |
|
|
JPH0140824B2 |
|
|
JPH0140825B2 |
|
|
JPH0140813B2 |
|
|
JPH0140021B2 |
|
|
JPH0140020B2 |
|
|
JPH0138438B2 |
Composition consisting of from less than 100% to more than about 80% of trans-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol and a definite amount, but not more than about 20%, of cis-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol.Process for prepar...
|
|
JPH0138104B2 |
|
|
JPH01502117A |
Therapeutical compositions containing products obtained from the addition of thiols to prostaglandines or analogues of prostaglandines. These compositions have an antitumoral activity.
|
|
JPH01186860A |
PURPOSE: To obtain a high-quality astaxanthin-containing powder leaving a chromoprotein at large amounts without braking, by subjecting raw crustacea to drying at low temperature and pulverization treatment. CONSTITUTION: Crustacea such ...
|
|
JPH01183559A |
PURPOSE: To obtain the title knitted fabric which has an appearance very close to a woven fabric and excellent stretchability characteristic in knitted fabrics, by arranging a knit element consisting of knit loops lined with welt loops a...
|
|
JPH01179855A |
PURPOSE:To make sure the identification and control of a subject air conditioner by controlling the air conditioner by a two-stage voice control of the call voice and the control voice. CONSTITUTION:A remote voice input device 1 has a mi...
|
|
JPH01160954A |
PURPOSE:To recover carotene with excellent separation efficiency by simple operation, by passing carotene-containing natural fats and oils through a modified glass wool packing and carrying out treatment. CONSTITUTION:Carotene-containing...
|
|
JPH0130817B2 |
A total synthesis of canthaxanthin or dinor-canthaxanthin, known food coloring agents, from pentols.
|
|
JPH01156956A |
PURPOSE: To obtain a compound consisting of an acidic polymer of prostaglandin E1, A1 or B1 and having protecting action to injury of organ cell by ischemia or anoxia, injury of nerve cell by wound and erythrocyte of drepanocythemia pati...
|
|
JPH0129168B2 |
|
|
JPH0129184B2 |
1α, 3β-dihydroxysteroid-5-ene, an intermediate of 1α-hydroxy vitamin D2 and D3, was prepd. Thus, 1α-hydroxy or 1α, 2α-epoxysteroid-4,6-diene-3-one having immediately removable 6-substitute radical was reduced with alk. metal/liq. N...
|
|
JPH01501310A |
PCT No. PCT/DK87/00104 Sec. 371 Date Apr. 26, 1988 Sec. 102(e) Date Apr. 26, 1988 PCT Filed Aug. 25, 1987 PCT Pub. No. WO88/01615 PCT Pub. Date Mar. 10, 1988. (I) Novel ester derivatives of carboxylic acid medicaments of formula (I), whe...
|
|
JPH0123445B2 |
|
|
JPH01110667A |
26,26,26,27,27,27-Hexadeutero-1 alpha ,25-dihydroxycholecalciferol and 24,24,26,26,26,27,27,27-octadeutero-1 alpha ,25-dihydroxycholecalciferol can be used as medicines, for example for the treatment of osteoporosis or psoriasis.
|
|
JPH01102059A |
NEW MATERIAL:A compound of formula I (A is carbonyl, hydroxymethylene; R1 is 1W10C alkyl, 5W6-membered cycloalkyl; R2 is H, 1W10C alkyl; R3, R4 and H, protecting group; R5 is H, hydroxy; broken lines means single or double bonds) and its...
|
|
JPH01100156A |
NEW MATERIAL:A compound of the formula (A is H, OH). EXAMPLE: (1S,6R)-1-Hydroxy-6-methoxymethoxy-3,5-cyclovitamin D3. USE: A synthetic intermediate of 1α-hydroxyl compound having vitamin D-like activity. PREPARATION: The reaction of 6R ...
|
|
JPH0116840B2 |
|
|
JPH0115484B2 |
A method of leukemia or leukemoid disease treatment by administration of a vitamin D derivative with a hydroxyl group at 1 alpha -position is disclosed. It is believed that the vitamin D derivative with a hydroxyl group at 1 alpha -posit...
|
